Revlimid’s New Label Features New Safety Language
Executive Summary
Labeling for newly diagnosed multiple myeloma includes new warning on risk of second primary malignancies, among other changes.
You may also be interested in...
Celgene Secures Revlimid Frontline Myeloma Approval
Labeling includes new warning for development of second primary malignancies and more language about other kinds of adverse events, but there is already widespread off-label use and analysts don’t expect the warnings to have much impact.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.